Latest Pharma Insights
Democratizing Global Access To Image Guided Therapy
As a Royal Philips intern in 2007, Mark Stoffels already knew he wanted to work in medtech and make an impact. Nearly 20 years later, the business unit leader of image guided therapy systems can safely say both boxes have been ticked – but that’s not the end of the story.
In Vivo - July 10, 2026
As a Royal Philips intern in 2007, Mark Stoffels already knew he wanted to work in medtech and make an impact. Nearly 20 years later, the business unit leader of image guided therapy systems can safely say both boxes have been ticked – but that’s not the end of the story.
In Vivo - July 10, 2026
L’Oréal Lands Gucci Beauty License Early As Coty Agrees To $400M Exit
L'Oréal will take over the Gucci Beauty license one year ahead of schedule, as current licensee Coty agrees to an early end of the partnership with Kering for $400m.
HBW Insight - July 10, 2026
L'Oréal will take over the Gucci Beauty license one year ahead of schedule, as current licensee Coty agrees to an early end of the partnership with Kering for $400m.
HBW Insight - July 10, 2026
FDA Bench Study Finds Tampon Metal Levels Too Low To Harm Users
FDA bench study confirmed trace toxic metals in commercially available tampons but found exposure levels pose negligible risk to users.
HBW Insight - July 10, 2026
FDA bench study confirmed trace toxic metals in commercially available tampons but found exposure levels pose negligible risk to users.
HBW Insight - July 10, 2026
Mega-Round Surge Leads Big Q2 Venture Funding Boom
Second-quarter 2026 data show biopharma venture capital fundraising surged to its highest level since Q1 2021 with a 68% rise in $100m-plus rounds, led by Isomorphic’s $2.1bn financing.
Scrip - July 9, 2026
Second-quarter 2026 data show biopharma venture capital fundraising surged to its highest level since Q1 2021 with a 68% rise in $100m-plus rounds, led by Isomorphic’s $2.1bn financing.
Scrip - July 9, 2026
InxMed’s Ifebemtinib Moves Ahead Amid Positive Phase II NSCLC Combo Data
The company published results in The Lancet Respiratory Medicine showing strong efficacy in KRAS G12C-mutant NSCLC for the FAK inhibitor combined with a KRAS G12C inhibitor.
Scrip - July 9, 2026
The company published results in The Lancet Respiratory Medicine showing strong efficacy in KRAS G12C-mutant NSCLC for the FAK inhibitor combined with a KRAS G12C inhibitor.
Scrip - July 9, 2026
Tarsus Will Move Into Chronic Retinal Disease With iRenix Takeout
Deal Snapshot: With a growing product for Demodex blepharitis, Tarsus will expand into retinal eye care with a $75m buyout of iRenix and its Phase III candidate for post-procedure ocular pain.
Scrip - July 9, 2026
Deal Snapshot: With a growing product for Demodex blepharitis, Tarsus will expand into retinal eye care with a $75m buyout of iRenix and its Phase III candidate for post-procedure ocular pain.
Scrip - July 9, 2026
API Snag To Hit Dr Reddy’s Semaglutide Supplies, CEO Expects Fix Later This Year
Dr Reddy's semaglutide supply is hit by impurity issues, with Canadian market deliveries also expected to be affected down the line. Partner Torrent is separately making a voluntary recall of certain batches of semaglutide injection following a product recall notification from Dr Reddy’s.
Scrip - July 9, 2026
Dr Reddy's semaglutide supply is hit by impurity issues, with Canadian market deliveries also expected to be affected down the line. Partner Torrent is separately making a voluntary recall of certain batches of semaglutide injection following a product recall notification from Dr Reddy’s.
Scrip - July 9, 2026
GSK Bids Farewell To Alector Dementia Deal
The UK giant is unsurprisingly terminating the companies' $2.2bn biobucks pact based on latozinemab and nivisnebart which have both failed clinical trials.
Scrip - July 9, 2026
The UK giant is unsurprisingly terminating the companies' $2.2bn biobucks pact based on latozinemab and nivisnebart which have both failed clinical trials.
Scrip - July 9, 2026
BioBytes: AI-Related Deals In Q2 ‘26
AI investment in healthcare remained robust in Q2 2026, driven by blockbuster fundraises, early-stage financings and strategic pharma alliances.
Scrip - July 9, 2026
AI investment in healthcare remained robust in Q2 2026, driven by blockbuster fundraises, early-stage financings and strategic pharma alliances.
Scrip - July 9, 2026
AstraZeneca’s Trial-Design Halo Slips As Wainua Fails Phase III In ATTR-CM
Shares of the pharma major fell 8% after the study missed its main goal, denting the drugmaker’s reputation for near-flawless trial design, though a monotherapy subgroup kept a sliver of hope alive.
Scrip - July 9, 2026
Shares of the pharma major fell 8% after the study missed its main goal, denting the drugmaker’s reputation for near-flawless trial design, though a monotherapy subgroup kept a sliver of hope alive.
Scrip - July 9, 2026
Novo Nordisk Launches Once-Weekly Insulin Awiqli In India To Treat Type 1, Type 2 Diabetes
Novo Nordisk has launched its once-weekly insulin brand Awiqli in India for adult type-1 and type-2 diabetes patients, pricing it competitively at about $27 for 700 insulin units. The India patent validity till March 2029 breathes new life into its diabetes franchise
Scrip - July 9, 2026
Novo Nordisk has launched its once-weekly insulin brand Awiqli in India for adult type-1 and type-2 diabetes patients, pricing it competitively at about $27 for 700 insulin units. The India patent validity till March 2029 breathes new life into its diabetes franchise
Scrip - July 9, 2026
HIPAA Cybersecurity Overhaul Delayed To July 2027 As HHS Reviews Thousands Of Comments
HHS has delayed finalization of its HIPAA cybersecurity rule to July 2027, more than a year past the original May 2026 target. The department is still reviewing nearly 5,000 public comments and is separately seeking input on AI adoption in clinical care.
Medtech Insight - July 9, 2026
HHS has delayed finalization of its HIPAA cybersecurity rule to July 2027, more than a year past the original May 2026 target. The department is still reviewing nearly 5,000 public comments and is separately seeking input on AI adoption in clinical care.
Medtech Insight - July 9, 2026
Execs On The Move: June 29–July 3, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - July 9, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - July 9, 2026
Roche Turns To Industrial Robotics Partner ABB Robotics In Lab Automation Push
Roche and ABB Robotics are jointly developing AI-powered robotic systems for pathology and central laboratories, targeting workflow bottlenecks driven by labor shortages and precision medicine demand.
Medtech Insight - July 9, 2026
Roche and ABB Robotics are jointly developing AI-powered robotic systems for pathology and central laboratories, targeting workflow bottlenecks driven by labor shortages and precision medicine demand.
Medtech Insight - July 9, 2026
VB Spine Bets On Fluoroscopy Fix To Bring AR Navigation To More ORs
VB Spine has secured exclusive rights to Augmedics' CT-Fluoro technology, enabling spine navigation without intraoperative CT — a move less about adding a feature and more about unlocking ambulatory surgery centers and smaller hospitals that premium navigation has never reached.
Medtech Insight - July 9, 2026
VB Spine has secured exclusive rights to Augmedics' CT-Fluoro technology, enabling spine navigation without intraoperative CT — a move less about adding a feature and more about unlocking ambulatory surgery centers and smaller hospitals that premium navigation has never reached.
Medtech Insight - July 9, 2026
Team-NB Pushes Back Against Lighter MDR/IVDR Oversight In New Position Paper
A new position paper from Team-NB shows that consensus on EU medtech regulation levels is far from settled, with notified bodies suggesting stricter surveillance tiers and recertifications than those proposed by other stakeholders.
Medtech Insight - July 9, 2026
A new position paper from Team-NB shows that consensus on EU medtech regulation levels is far from settled, with notified bodies suggesting stricter surveillance tiers and recertifications than those proposed by other stakeholders.
Medtech Insight - July 9, 2026
L’Oréal Lands Gucci Beauty License Early As Coty Agrees To $400M Exit
L'Oréal will take over the Gucci Beauty license one year ahead of schedule, as current licensee Coty agrees to an early end of the partnership with Kering for $400m.
HBW Insight - July 10, 2026
L'Oréal will take over the Gucci Beauty license one year ahead of schedule, as current licensee Coty agrees to an early end of the partnership with Kering for $400m.
HBW Insight - July 10, 2026
FDA Bench Study Finds Tampon Metal Levels Too Low To Harm Users
FDA bench study confirmed trace toxic metals in commercially available tampons but found exposure levels pose negligible risk to users.
HBW Insight - July 10, 2026
FDA bench study confirmed trace toxic metals in commercially available tampons but found exposure levels pose negligible risk to users.
HBW Insight - July 10, 2026
Granules India Secures A Further First-To File Status
The US Food and Drug Administration has designated first-to-file status to Granules India for the generic version of Lumryz.
Generics Bulletin - July 9, 2026
The US Food and Drug Administration has designated first-to-file status to Granules India for the generic version of Lumryz.
Generics Bulletin - July 9, 2026
Most Of Amgen’s Counterattack Crumbles In Aflibercept Biosimilar Litigation
Amgen remains first and alone on the US aflibercept biosimilar market, but a West Virginia court has narrowed most of its defenses against Regeneron’s latest patent case.
Generics Bulletin - July 9, 2026
Amgen remains first and alone on the US aflibercept biosimilar market, but a West Virginia court has narrowed most of its defenses against Regeneron’s latest patent case.
Generics Bulletin - July 9, 2026
Democratizing Global Access To Image Guided Therapy
As a Royal Philips intern in 2007, Mark Stoffels already knew he wanted to work in medtech and make an impact. Nearly 20 years later, the business unit leader of image guided therapy systems can safely say both boxes have been ticked – but that’s not the end of the story.
In Vivo - July 10, 2026
As a Royal Philips intern in 2007, Mark Stoffels already knew he wanted to work in medtech and make an impact. Nearly 20 years later, the business unit leader of image guided therapy systems can safely say both boxes have been ticked – but that’s not the end of the story.
In Vivo - July 10, 2026